Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
5F205Dba5w3uTk2g
